Neoadjuvant chemotherapy has been used to treat the early-stage triple-negative breast cancer and HER2-positive breast cancers,which can prolong the survival and improve the quality of life of the patient.MRI is the most effective imaging method to evaluate the efficacy of neoadjuvant chemotherapy for breast cancer patients.The dynamic contrast-enhanced MRI(DCE-MRI)can confirm the residual disease more correctly and also can assess it size semi-quantitatively by measuring hemodynamic parameters and generating time-signal intensity curve(TIC).The diffusion weighted imaging(DWI)can assess the variation of ADC value quantitatively to measure the degree of tumor remission,and the magnetic resonance spectroscopy(MRS)can show the internal metabolic changes of the tumors to assess the therapeutic efficacy.At present,MRI-based radiomics and deep learning have become the research hotspot in evaluation of treatment response of the neoadjuvant chemotherapy for breast cancer patients.
breast cancerneoadjuvant chemotherapymagnetic resonance imagingefficacy evaluation
维普
万方数据
